Engflag

Ferrimed

Quick links to important sections

Ferrimed

Ferrimed_NL

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferrimed

Quick Facts

Property Description
Active Ingredients Iron (III)-hydroxide polymaltose complex, Folic Acid
Primary Forms Capsules, Syrup, Chewable Tablets
Pharmacological Class Haematinic, Erythropoietic
General Purpose Replenishment of iron and folate stores
Origin Complex inorganic-synthetic (Iron) and vitamin (Folic Acid)

What Type of Medication is Ferrimed? (Definition and Classification)

Ferrimed is a proprietary combination medication classified as a haematinic and an erythropoietic, which are agents that promote the formation of red blood cells. Its fundamental role is to provide essential materials for the body to correct deficits in iron and folate, nutrients crucial for maintaining health. The medication is an oral iron preparation, administered via the oral route (per os). This product contains two complementary active ingredients: the specialized Iron (III)-hydroxide polymaltose complex (IPC) and Folic Acid (folate). This dual composition defines its therapeutic identity, allowing it to address the co-occurrence of iron and folate deficiencies, a need often recognized in patient populations like pregnant women.

Composition, Unique Forms, and Origin

The primary component is the Iron (III)-hydroxide polymaltose complex, a unique non-ionic structure where the Iron(III) core is tightly bound to a polymaltose carrier. The stability of this macromolecular complex is a key feature; this unique structure is designed to limit the release of free iron into the gastrointestinal tract. This supports the understanding that this preparation is intended for controlled and efficient absorption.

This structure distinguishes it from traditional ferrous salts used in older oral iron preparations. Ferrimed is available in various dosage forms, including capsules, syrup (oral solution), and chewable tablets, specifically catering to diverse patient compliance needs, such as children requiring a palatable syrup or individuals preferring a solid oral dose.

General Purpose and High-Level Action

The general purpose of Ferrimed is the systematic replenishment of iron stores and the correction of folate deficiencies, both necessary for cell synthesis. By restoring these nutrient reserves, the high-level action of the medication supports the core process of haemoglobin formation. Iron is an essential component of haemoglobin, which supports the body’s ability to transport oxygen effectively. Haemoglobin is vital for efficient oxygen transport throughout the body, ensuring the body has the building blocks required to sustain fundamental life processes.

Regulatory References

  1. WHO Model List of Essential Medicines
  2. NIH Office of Dietary Supplements Iron Fact Sheet

What side effects are possible with Ferrimed?

Possible Side Effects and Safety Information

The safety profile for this combination of Iron (III)-hydroxide polymaltose complex and Folic Acid primarily documents effects related to the gastrointestinal system. The adverse reactions are classified according to regulatory frequency standards.

Adverse Reactions and Frequency

Classification System-Organ Class Reactions Documented in Regulatory Sources
Uncommon / Rarely Gastrointestinal Disorders Abdominal pain, nausea, vomiting, constipation, diarrhea, feeling of fullness.
Rarely Immune/Skin Disorders Allergic reactions, including skin rash (exanthema), itching, and urticaria.

Serious Adverse Reactions and Safety Constraints

The regulatory documents highlight certain serious risks and restrictions for use. Accidental ingestion of iron products is documented as a leading cause of fatal iron toxicity in children under six years of age. Severe allergic reactions are possible, though rare. Overdose, in severe cases, can lead to serious sequelae, including metabolic acidosis, convulsions, and coma.

Specific Safety Considerations

Treatment is contraindicated in patients with known hypersensitivity to the active substances, as well as in those with conditions of iron overload (e.g., hemochromatosis). A significant safety consideration is that the Folic Acid component may mask the hematological signs of a Vitamin B12 deficiency while allowing potential irreversible neurological damage to advance. Furthermore, the official labeling notes that a dark or black discoloration of the stool is an expected, harmless outcome and does not signify a clinical problem.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for iron-containing products, including Ferrimed (Iron (III)-hydroxide polymaltose complex and Folic Acid), details the serious, potentially fatal risks associated with overdosage, primarily from the iron component.

Documented Manifestations and Severe Outcomes

An overdose initially presents with gastrointestinal signs such as abdominal pain, nausea, diarrhoea, and vomiting (which may be blood-stained). Severe systemic toxicity progresses rapidly, leading to circulatory collapse and shock. Officially documented life-threatening outcomes include acute organ damage, such as acute hepatic necrosis and acute renal failure, alongside neurological effects like convulsions and coma.

Mandatory Emergency Action

Regulatory authorities strictly mandate that an individual seek immediate medical attention and contact a poison unit upon suspicion of an overdose. Immediate transfer to a hospital is required due to the high risk of systemic toxicity. Overdosage is classified as potentially fatal in regulatory documents.

Management and Specific Antidote

The treatment protocol documented by regulators involves the use of the specific antidote, Deferoxamine (Desferrioxamine), for severe iron toxicity. Management procedures also include techniques such as gastro-intestinal evacuation and continuous monitoring of serum iron levels during observation.

Population-Specific Risk

A critical warning detailed in the labeling is the potential for fatal toxicity in children below 6 years of age from accidental ingestion of iron-containing products.

Therapeutic Uses of Ferrimed

Quick Facts

  • Primary Use: Management of iron deficiency anemia in certain adult patients.
  • Patient Group: Adults who have experienced an unsatisfactory response or intolerance to oral iron supplements.
  • Specific Indication: Treatment of iron deficiency anemia in adult patients with non-dialysis dependent chronic kidney disease (CKD).

What Ferrimed Treats: Main Uses and Benefits

Ferrimed is a prescription medication used to manage iron deficiency anemia, a common condition where the body does not have sufficient iron to produce adequate levels of red blood cells. The therapy is intended to help restore low iron reserves in the body. Replenishing iron stores is necessary to assist the body's natural function of forming red blood cells, which are responsible for oxygen transport throughout the system.

This medication is typically considered a therapeutic option for adult individuals who have not responded adequately to or cannot tolerate oral iron supplementation. A specific approved use includes the treatment of iron deficiency anemia in adults diagnosed with non-dialysis dependent chronic kidney disease. Treatment with Ferrimed aims to address the deficiency to support overall patient well-being and to alleviate symptoms associated with low iron levels.

Eligibility and Restrictions for Use

Who Can and Cannot Use Ferrimed? (Official Eligibility)

This section outlines population eligibility and non-eligibility for Ferrimed (Iron (III)-hydroxide polymaltose complex with Folic Acid) based on regulatory documents.

Populations for whom use is Contraindicated: Use is absolutely prohibited for patients with:

  • Known hypersensitivity to the active ingredients or excipients.
  • Conditions causing iron overload, such as hemochromatosis or hemosiderosis.
  • Anemias not caused by iron deficiency, including megaloblastic anemia due to Vitamin B12 deficiency, or thalassemia.
  • Severe liver or severe kidney diseases.

Restricted and Age-Related Eligibility:

  • Severe Restrictions: A possible Vitamin B12 deficiency must be excluded before treatment begins. Use requires caution in patients with a history of alcoholism, intestinal inflammation, or those receiving repeated blood transfusions.
  • Pediatrics: The medicine is not recommended for children 12 years and younger due to insufficient clinical data. A strict warning exists regarding the risk of fatal toxicity in children below 6 years from accidental iron ingestion.
  • Maternal Status: Use is generally permitted during both pregnancy and lactation.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Ferrimed (Iron (III)-hydroxide polymaltose complex and Folic Acid) is structured around managing co-administered medications to prevent reduced absorption and to manage specific pharmacodynamic effects.

Documented Interaction Patterns

The most significant interactions involve reciprocal reductions in absorption (chelation) and pharmacodynamic interference. Co-administration with Parenteral Iron Preparations is not indicated and should be avoided due to significant inhibition of oral iron absorption.

Medicines Requiring Timing Separation

To limit absorption interference, the following agents require mandatory dose separation:

Co-administered Substance Interaction Outcome Separation Rule
Tetracyclines or Quinolones Reduces antibiotic effect and iron absorption At least two or three hours before or after the antibiotic
Antacids or Calcium Supplements Reduces iron absorption At least two hours after co-administration

Medicines with Altered Efficacy

The Folic Acid component may affect Phenytoin concentrations, potentially leading to lower serum levels and an increased frequency of epileptic seizures. Iron formulations may also reduce the hypotensive effect of Methyldopa and decrease the absorption of agents like Thyroxine and Penicillamine.

Food and Unique Iron Complex Properties

While Tea, Coffee, and Milk may reduce iron absorption, the Iron (III)-hydroxide polymaltose complex is documented as unlikely to engage in the typical ionic interactions with food components such as phytin and tannin, a distinction from simple iron salts.

Mechanism of Action

Mechanism of Action: How Ferrimed Works

The Ferric Hydroxide Polymaltose Complex (IPC) in Ferrimed releases non-ionic ferric iron (Fe^3+) in the gastrointestinal tract upon exposure to digestive enzymes. This Fe^3+ is then taken up by the intestinal mucosal cells (enterocytes) via a process of receptor-mediated endocytosis.

Following absorption, the iron is released from the enterocytes and subsequently incorporated into the plasma protein transferrin. Transferrin functions as the primary vehicle for systemic iron transport, delivering the micronutrient to sites with high demand, including the bone marrow, liver, and spleen.

Once delivered, the iron is utilized as a co-factor in critical biochemical pathways. Specifically, it is a precursor for the synthesis of heme, an essential prosthetic group of the oxygen-carrying protein hemoglobin, and is integral to various iron-dependent mitochondrial processes necessary for cellular respiration.

Dosage and Administration Information

How to Use Ferrimed

The usage of Ferrimed is based on a structured oral regimen, with administration instructions that differ based on the patient's age and specific dosage form. This medication is strictly for oral administration (per os), available as capsules, syrup, and chewable tablets.

Dosing and Frequency Principles

Administration is generally mandated to be taken with meals or immediately after food intake. The total daily dose is typically administered in divided doses across the day.

Usage Scenario Elemental Iron Dose Range (Adults) Frequency Pattern
Therapeutic Dose (Capsules/Tablets) 100 mg to 200 mg per day In divided doses with meals
Supplementary Dose (Capsules) 50 mg to 100 mg per day In divided doses with meals

Administration Context and Duration

For the syrup formulation, the dose may begin lower (25 mg to 50 mg) and be gradually increased up to 200 mg per day, split into two to three divided doses with meals.

Pediatric use requires dosing adjusted to body weight, with children receiving approximately 3 mg elemental iron per kilogram of body weight per day. Infants receive up to 6 mg/kg and must have the syrup administered in 3 to 4 divided doses with feeds. Chewable tablets may be chewed or swallowed whole.

The course of treatment is required to extend at least an additional month after blood values have normalized to ensure the full replenishment of the body's iron stores, a critical part of the use protocol. The required dose must always account for any other concurrent supplemental iron a patient may be receiving.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ferrimed

Evidence for Use in General Adult Iron Deficiency Anemia (IDA)

The research base for the Iron (III)-hydroxide Polymaltose Complex (IPC) component of Ferrimed largely consists of Randomized Controlled Trials (RCTs) and comprehensive Meta-analyses. These studies were conducted to examine the complex in non-pregnant adults diagnosed with Iron Deficiency Anemia (IDA). Researchers monitored changes in key blood markers, such as Hemoglobin (Hb), and how studies measured changes in Serum Ferritin (which reflects the body’s iron stores).

Comparative evidence described short-term changes in blood markers associated with the IPC complex over follow-up periods, typically lasting around two to three months. Research indicates a pattern of fewer gastrointestinal events reported in association with the IPC compared to traditional iron salts, a factor that studies explored in relation to patient tolerability. However, results apply only to the specific populations and study conditions examined.

Studies in Specific Patient Groups

Research has explored the use of the iron complex in specific populations where iron deficiency is common or where managing anemia is more complex.

The iron complex was studied for Iron Deficiency Anemia during pregnancy. These studies monitored outcomes related to systemic or functional imbalance by tracking changes in maternal Hemoglobin and how studies measured changes in Serum Ferritin levels. Long-term maternal and neonatal outcomes are not fully established by the existing studies, and data remain limited.

The iron complex was evaluated in adults with Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD) who have IDA. Studies in this group tracked changes in Hemoglobin and the maintenance of iron biomarkers. Specific comparative evidence for the IPC plus Folic Acid combination focusing exclusively on this subgroup remains sparse, as the evidence is often derived from broader studies evaluating iron supplementation approaches in CKD.

What Remains Uncertain in the Research Landscape

For the pediatric population, subsequent systematic reviews report that the findings from the existing trials are often mixed and contradictory. Research quality varies across these studies, and certainty remains low. Furthermore, clinical trials are predominantly short-term, observing responses for approximately three months. There is limited information for long-term outcomes and the sustained durability of the iron repletion effect after treatment is completed.

Key Studies & References

  1. Iron (III)-hydroxide Polymaltose Complex in Iron Deficiency Anemia (Meta-analysis of comparative adult studies)
  2. Efficacy and safety of oral iron(III) polymaltose complex versus ferrous sulfate in pregnant women with iron-deficiency anemia: a multicenter, randomized, controlled study
  3. Comparison of efficacy and tolerability of iron polymaltose complex with ferrous sulphate in treatment of children with iron deficiency anemia (RCT)

Frequently Asked Questions (FAQ)

Common questions about Ferrimed (FAQ)

Q: How long does it take for Ferrimed to start working or for my iron levels to improve?

Studies and official information indicate that monitoring the body's response, such as changes in hemoglobin and iron stores, often involves follow-up periods that can last a minimum of two to three months.

The course of treatment is required to extend at least an additional month after blood values have normalized to support the full replenishment of the body's iron stores.

Q: Can Ferrimed be taken on an empty stomach?

According to the official product information, Ferrimed is generally advised to be taken with meals or immediately following food intake.

Taking it with food is part of the administration instructions outlined in official labeling, which may also influence tolerability.

Q: What is the difference between Ferrimed and ferrous salt iron supplements?

Ferrimed contains the Iron (III)-hydroxide polymaltose complex (IPC), which is a specialized, non-ionic iron structure.

This unique complex is designed to limit the release of free iron ions into the gastrointestinal tract, distinguishing it from traditional iron supplements known as ferrous salts.

Q: What should I do if I miss a dose of Ferrimed?

Official guidance for a missed dose generally advises skipping the forgotten dose and continuing with the regular dosing schedule.

It is strongly advised in official patient information that a double dose should never be taken to compensate for a forgotten one.

Q: What is the maximum daily dose of Ferrimed for an adult?

Official product information for adults receiving therapeutic treatment specifies a total daily dose range that is generally between 100 mg to 200 mg of elemental iron.

The specified total daily dose range is intended to be administered in divided doses.

Q: What happens if I take too much Ferrimed?

Official warnings highlight that accidental ingestion and overdose of iron products are serious risks and are considered medical emergencies.

Overdose can potentially lead to severe effects, including metabolic acidosis, convulsions, and even coma, and requires immediate medical attention.

How should Ferrimed be stored and disposed of?

How to Store and Dispose of Ferrimed

The storage and disposal of Ferrimed (Iron (III)-hydroxide polymaltose complex) must strictly comply with regulatory requirements to maintain product integrity and ensure safety.

Storage Conditions

Ferrimed must be stored at Room Temperature, generally defined as between 15 C and 25 C (or not above 30 C). The medicine should be kept in a dry place and protected from light by remaining in its original, tightly closed container.

Child Safety and Disposal

It is officially required to Keep this product out of the sight and reach of children due to the risk of accidental iron poisoning. Unused or expired Ferrimed must be handled as pharmaceutical waste; it should be disposed of according to local regulations, such as through an authorized drug take-back program. It is prohibited to release the product into the environment, drains, or sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ferrimed found in:

A-Z Index: